麻疹、腮腺炎、风疹疫苗(PRIORIX):美国免疫实践咨询委员会建议——美国,2022年
美国免疫实践咨询委员会(ACIP)于2022年6月23日一致推荐PRIORIX作为预防麻疹、腮腺炎和风疹的选项,按现有推荐程序及超说明书使用,并认为其安全、免疫原性良好且非劣于M-M-R II,两者可完全互换。
要点
- ACIP一致推荐PRIORIX作为预防麻疹、腮腺炎和风疹的选项,按现有推荐程序及超说明书使用。
- ACIP认为PRIORIX安全、免疫原性良好且非劣于M-M-R II。
- PRIORIX与M-M-R II在所有推荐接种MMR疫苗的适应症上可完全互换。
核心结论
- ACIP一致推荐PRIORIX作为预防麻疹、腮腺炎和风疹的选项,按现有推荐程序及超说明书使用。
- ACIP认为PRIORIX安全、免疫原性良好且非劣于M-M-R II,两者可完全互换。
研究设计与样本
- 美国免疫实践咨询委员会(ACIP)于2022年6月23日一致推荐PRIORIX作为预防麻疹、腮腺炎和风疹的选项。
主要发现
- PRIORIX所含三种减毒活病毒与M-M-R II对应组分遗传相似或相同。
- 美国麻疹和风疹输入风险及腮腺炎再现,维持高MMR疫苗接种覆盖率重要。
- 自2006年以来美国腮腺炎病例和暴发增加,2016年以来地理分布更广。
关键数值与推荐
- 2022年6月6日,美国食品药品监督管理局批准PRIORIX用于≥12月龄人群预防麻疹、腮腺炎和风疹。
- ACIP推荐PRIORIX按现有推荐程序及超说明书使用(即说明书未包含的适应症)。
- PRIORIX与M-M-R II在所有推荐接种MMR疫苗的适应症上可完全互换。
临床怎么用
- PRIORIX可作为预防麻疹、腮腺炎和风疹的选项,按现有推荐程序及超说明书使用。
- PRIORIX与M-M-R II在所有推荐接种MMR疫苗的适应症上可完全互换。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination is the main means for preventing measles, mumps, and rubella virus infections and their related complications (1,2). Achieving and maintaining high 2-dose measles, mumps, and rubella vaccination coverage in the United States has led to elimination of endemic measles in 2000, rubella and congenital rubella syndrome in 2004, and a sharp decrease in mumps cases. However, measles and rubella remain endemic in many countries, leading to importations of cases and occasional local transmission within the United States (3). Reported U.S. mumps cases declined >99% from the prevaccine period (4); however, mumps is endemic worldwide, and since 2006, the number of mumps cases and mumps outbreaks has increased in the United States, with wider geographic spread since 2016 (4). Given the risk for importation of measles and rubella and the resurgence of mumps, maintaining high measles, mumps, and rubella (MMR) vaccination coverage is important. Since 1978, only one MMR vaccine, M-M-R II (Merck and Co., Inc.), has been available in the United States. On June 6, 2022, the Food and Drug Administration approved a second MMR vaccine, PRIORIX (GlaxoSmithKline Biologicals), for the prevention of measles, mumps, and rubella in persons aged ≥12 months. The three live attenuated viruses contained in PRIORIX are genetically similar or identical to the corresponding components in M-M-R II (Table) (5-7). On June 23, 2022, the Advisory Committee on Immunization Practices (ACIP) unanimously recommended PRIORIX as an option to prevent measles, mumps, and rubella according to the existing recommended schedules and for off-label uses (i.e., indications not included in the package insert)* (1,2). ACIP considered PRIORIX to be safe, immunogenic, and noninferior to M-M-R II. Both PRIORIX and M-M-R II are fully interchangeable for all indications for which MMR vaccination is recommended. This report contains ACIP recommendations specific to PRIORIX and supplements the existing ACIP recommendations for MMR use (1,2).
引用
- Krow-Lucal E, Marin M, Shepersky L, et al. Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36395065. doi:10.15585/mmwr.mm7146a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。